Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Amani Alqahtani, Diala Alhousari, Amir Ali, George Yaghmour, Etan Orgel, Emily Curran, Wendy Stock, Deepa Bhojwani & Houda Alachkar. (2023) Asparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understanding. Expert Opinion on Drug Metabolism & Toxicology 19:6, pages 357-366.
Read now
Read now
Melissa Sandley & Jonathan Angus. (2023) Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management. Leukemia & Lymphoma 64:4, pages 776-787.
Read now
Read now
Krishna R Juluri, Chloe Siu & Ryan D Cassaday. (2022) Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy. Blood and Lymphatic Cancer: Targets and Therapy 12, pages 55-79.
Read now
Read now
Saveria Capria, Matteo Molica, Sara Mohamed, Simona Bianchi, Maria Luisa Moleti, Silvia Maria Trisolini, Sabina Chiaretti & Anna Maria Testi. (2020) A review of current induction strategies and emerging prognostic factors in the management of children and adolescents with acute lymphoblastic leukemia. Expert Review of Hematology 13:7, pages 755-769.
Read now
Read now
Bernard L. Marini, Julia Brown, Lydia Benitez, Emily Walling, Raymond J. Hutchinson, Rajen Mody, Rama Jasty Rao, Lynn Slagle, Lauren Bishop, Kristen Pettit, Dale L. Bixby, Patrick W. Burke & Anthony J. Perissinotti. (2019) A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage. Leukemia & Lymphoma 60:12, pages 2854-2868.
Read now
Read now
Articles from other publishers (31)
Sarah Menig, Andrew Dinh, Jonathan Angus, Sarah Tucker, Kasey J. Leger, Teresa Rushing & Etan Orgel. (2023) Lack of benefit from premedication for pegylated asparaginase during pediatric acute lymphoblastic leukemia/lymphoma therapy: A side‐by‐side comparison. Pediatric Blood & Cancer 71:1.
Crossref
Crossref
Dongyu Guo, Mengyu Gu, Fuquan Du, Yuting Zhao, Mingjie Gao & Jing Hao. (2023) Review of molecular biological studies on acute lymphoblastic leukemia treated by modified shengmaiyin. Medicine 102:23, pages e34013.
Crossref
Crossref
Hisashi Ishida, Toshihiko Imamura, Yasuhisa Tatebe, Takashi Ishihara, Kimiyoshi Sakaguchi, Souichi Suenobu, Atsushi Sato, Yoshiko Hashii, Takao Deguchi, Yoshihiro Takahashi, Daiichiro Hasegawa, Takako Miyamura, Akihiro Iguchi, Koji Kato, Akiko Saito‐Moriya, Junichi Hara & Keizo Horibe. (2023)
Impact of asparaginase discontinuation on outcomes of children with acute lymphoblastic leukaemia receiving the Japan Association of Childhood Leukaemia Study
ALL
‐02 protocol
. British Journal of Haematology 201:6, pages 1200-1208.
Crossref
Crossref
Carmelo Rizzari, Anja Möricke, Maria Grazia Valsecchi, Valentino Conter, Martin Zimmermann, Daniela Silvestri, Andishe Attarbaschi, Felix Niggli, Draga Barbaric, Jan Stary, Sarah Elitzur, Gunnar Cario, Luciana Vinti, Joachim Boos, Massimo Zucchetti, Claudia Lanvers-Kaminsky, Arend von Stackelberg, Andrea Biondi & Martin Schrappe. (2023) Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol. HemaSphere 7:6, pages e893.
Crossref
Crossref
Marilyne Poirée, Florent Neumann, Caroline Thomas, Pauline Simon, Anne France Ray Lunven, Dominique Plantaz, Sandrine Thouvenin Doulet & Marion Strullu. (2022) Prise en charge des toxicités de la pégaspargase (hors anomalies de la coagulation). Recommandations du comité leucémie de la Société française de lutte contre les cancers de l’enfant et de l’adolescent. Bulletin du Cancer 109:11, pages 1125-1131.
Crossref
Crossref
Randal K Buddington, Karyl K Buddington & Scott C. Howard. (2022) Multiple Asparaginase Infusions Cause Increasingly Severe Acute Hyperammonemia. Medical Sciences 10:3, pages 43.
Crossref
Crossref
Amanda Cabral dos Santos, Julia Maria Bispo dos Santos, Elisangela da Costa Lima & Marcelo Gerardin Poirot Land. (2021) L‐asparaginase doses number as a prognostic factor in childhood acute lymphoblastic leukemia: A survival analysis study. Cancer Reports 5:8.
Crossref
Crossref
Sara Zarnegar‐Lumley, Cosby A. StoneJr.Jr., Christine M. Smith, Laura L. Hall, Kate E. Luck, Grace Koo, Jessica H. Plager, Elizabeth J. Phillips & Debra L. Friedman. (2022) Oncologist counseling practice and COVID‐19 vaccination outcomes for patients with history of PEG‐asparaginase hypersensitivity. Pediatric Blood & Cancer 69:7.
Crossref
Crossref
Luke Maese & Rachel E. Rau. (2022) Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. Frontiers in Pediatrics 10.
Crossref
Crossref
Dan Douer, Nicola Gökbuget, Wendy Stock & Nicolas Boissel. (2022) Optimizing use of L-asparaginase–based treatment of adults with acute lymphoblastic leukemia. Blood Reviews 53, pages 100908.
Crossref
Crossref
Amanda C Santos, Marcelo G P Land & Elisangela C Lima. (2021) Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions. Journal of Oncology Pharmacy Practice 28:3, pages 551-559.
Crossref
Crossref
Kyle J. Babcock, Amy Kinnunen, Tosha Egelund, John S. Ng & Michael J. Joyce. (2022) Efficacy of a Standardized Premedication and Therapeutic Drug Monitoring Protocol for Pegaspargase to Prevent Hypersensitivity Reactions. The Journal of Pediatric Pharmacology and Therapeutics 27:3, pages 232-236.
Crossref
Crossref
Michael J Burke & Beata Zalewska-Szewczyk. (2022) Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences. Future Oncology 18:10, pages 1285-1299.
Crossref
Crossref
Meghan Pike, Ketan Kulkarni & Tamara MacDonald. (2021) Asparaginase activity monitoring and management of asparaginase hypersensitivity reactions in Canada. Journal of Oncology Pharmacy Practice, pages 107815522110554.
Crossref
Crossref
Montserrat Mesegué, Anna Alonso‐Saladrigues, Sara Pérez‐Jaume, Ariadna Comes‐Escoda, José Luís Dapena, Anna Faura, Nuria Conde, Albert Català, Anna Ruiz‐Llobet, Edgar Zapico‐Muñiz, Mireia Camós & Susana Rives. (2021)
Lower incidence of clinical allergy with PEG‐asparaginase upfront versus the sequential use of native
E. coli
asparaginase followed by PEG‐ASP in pediatric patients with acute lymphoblastic leukemia
. Hematological Oncology 39:5, pages 687-696.
Crossref
Crossref
Kathleen Busack. (2021) Pegaspargase: Two Pediatric Case Studies of Delayed Urticaria Preceding Anaphylactic Reactions Postadministration. Clinical Journal of Oncology Nursing 25:5, pages 511-513.
Crossref
Crossref
Nóra Kutszegi, András Gézsi, Ágnes F. Semsei, Judit Müller, Réka Simon, Erika Rozália Kovács, Katalin Hegedüs, Gábor T. Kovács, Csaba Szalai & Dániel J. Erdélyi. (2020)
Two tagging single‐nucleotide polymorphisms to capture
HLA
‐
DRB1*07:01–DQA1*02:01–DQB1*02:02
haplotype associated with asparaginase hypersensitivity
. British Journal of Clinical Pharmacology 87:6, pages 2542-2548.
Crossref
Crossref
David O. Riley, Jenna M. Schlefman, Hans Christoph Vitzthum Von Eckstaedt V, Amy L. Morris, Michael K. Keng & Firas El Chaer. (2021) Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit. Current Hematologic Malignancy Reports 16:3, pages 314-324.
Crossref
Crossref
Ana Paula Battistel, Bruno Simas da Rocha, Maitê Telles dos Santos, Liane Esteves Daudt & Mariana Bohns Michalowski. (2021) Allergic reactions to asparaginase: retrospective cohort study in pediatric patients with acute lymphoid leukemia. Hematology, Transfusion and Cell Therapy 43:1, pages 9-14.
Crossref
Crossref
Alaeddin Khalil, Gudrun Würthwein, Jana Golitsch, Georg Hempel, Manfred Fobker, Joachim Gerss, Anja Möricke, Martin Zimmermann, Petr Smisek, Massimo Zucchetti, Christa Nath, Andishe Attarbaschi, Arend Von Stackelberg, Nicola Gökbuget, Carmelo Rizzari, Valentino Conter, Martin Schrappe, Joachim Boos & Claudia Lanvers-Kaminsky. (2020) Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated <i>E. coli</i> asparaginase in children with acute lymphocytic leukemia. Haematologica 107:1, pages 49-57.
Crossref
Crossref
André Baruchel, Patrick Brown, Carmelo Rizzari, Lewis Silverman, Inge van der Sluis, Benjamin Ole Wolthers & Kjeld Schmiegelow. (2020) Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion. ESMO Open 5:5, pages e000977.
Crossref
Crossref
Irem Turgay Yagmur, Zeliha Guzelkucuk, Nese Yarali, Derya Ozyoruk, Muge Toyran, Ersoy Civelek, Namık Yasar Ozbek & Emine Dibek Misirlioglu. (2020) Evaluation of hypersensitivity reactions to cancer chemotherapeutic agents in pediatric patients. Annals of Allergy, Asthma & Immunology 124:4, pages 350-356.
Crossref
Crossref
Komail Nadeem, David Colantonio, Ida Kircanski, Ahmed Naqvi, Johann Hitzler, James A. Whitlock & L. Lee Dupuis. (2019) Clinical decisions following implementation of asparaginase activity monitoring in pediatric patients with acute lymphoblastic leukemia: Experience from a single‐center study. Pediatric Blood & Cancer 67:2.
Crossref
Crossref
Ibrahim Aldoss & Dan Douer. (2020) How I Treat the Toxicities of Pegasparaginase in Adults with Acute Lymphoblastic Leukemia. Blood.
Crossref
Crossref
Julia E. M. Upton. 2020. Anaphylaxis. Anaphylaxis
85
100
.
Yiwei Liu, Colton A. Smith, John C. Panetta, Wenjian Yang, Lauren E. Thompson, Jacob P. Counts, Alejandro R. Molinelli, Deqing Pei, Nancy M. Kornegay, Kristine R. Crews, Hope Swanson, Cheng Cheng, Seth E. Karol, William E. Evans, Hiroto Inaba, Ching-Hon Pui, Sima Jeha & Mary V. Relling. (2019) Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. Journal of Clinical Oncology 37:23, pages 2051-2061.
Crossref
Crossref
O. Sanmartín, C. Beato, H. Jin Suh-Oh, I. Aragón, A. España, M. Majem, S. Segura, A. Gúrpide, R. Botella & C. Grávalos. (2019) Clinical Management of Cutaneous Adverse Events in Patients on Chemotherapy: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology. Actas Dermo-Sifiliográficas (English Edition) 110:6, pages 448-459.
Crossref
Crossref
O. Sanmartín, C. Beato, H. Jin Suh-Oh, I. Aragón, A. España, M. Majem, S. Segura, A. Gúrpide, R. Botella & C. Grávalos. (2019) Manejo clínico de los eventos adversos cutáneos en pacientes tratados con quimioterapia: consenso nacional de la Academia Española de Dermatología y Venereología y de la Sociedad Española de Oncología Médica. Actas Dermo-Sifiliográficas 110:6, pages 448-459.
Crossref
Crossref
Stuart A. McNelles, Victoria M. Marando & Alex Adronov. (2019) Globular Polymer Grafts Require a Critical Size for Efficient Molecular Sieving of Enzyme Substrates. Angewandte Chemie International Edition 58:25, pages 8448-8453.
Crossref
Crossref
Stuart A. McNelles, Victoria M. Marando & Alex Adronov. (2019) Globular Polymer Grafts Require a Critical Size for Efficient Molecular Sieving of Enzyme Substrates. Angewandte Chemie.
Crossref
Crossref
Amanda Cabral dos Santos, Marcelo Gerardin Poirot Land, Nathalia Peroni da Silva, Kelly Oliveira Santos & Elisangela da Costa Lima-Dellamora. (2017) Reactions related to asparaginase infusion in a 10-year retrospective cohort. Revista Brasileira de Hematologia e Hemoterapia 39:4, pages 337-342.
Crossref
Crossref